Support for Africa’s Vaccine Production is Good for the World
IMF Blog, January 12, 2022
Source details
- Canonical URL
- Support for Africa’s Vaccine Production is Good for the World
Other formats
Bibliographic details
- Authors: Kristalina Georgieva
- Published: January 12, 2022
Overview
- Author: Kristalina Georgieva
- Date: January 12, 2022
- Core message: Robust and reliable vaccine capacity in Africa is a global public good and deserves global support.
- Context: Pandemic entering third year; Omicron variant emergence underscores global implications of Africa’s vaccine access.
Immediate challenges and meeting today’s needs
- Africa’s overall COVID vaccination rate on the continent is still below 10 percent.
- Africa remains reliant on COVID‑19 vaccine imports and donations.
- Immediate priorities:
- Guarantee predictability in vaccine deliveries — including through COVAX and the African Vaccine Acquisition Trust (AVAT).
- Fund health systems to vaccinate populations swiftly as new supplies arrive, including outreach to reduce misinformation and vaccine hesitancy.
- Ensure access to tests, treatments, and protective equipment.
- IMF staff vaccination targets and progress:
- Plan: vaccinate 40 percent of the population of all countries by end-2021 and 70 percent** by mid-2022.
- Outcome: Only seven countries in Africa reached the 40 percent target in 2021.
- Observation: For many countries, the 70 percent target seems increasingly ambitious.
- Financing gap:
- Closing the $23 billion financing gap of the Access to COVID‑19 Tools (ACT) Accelerator is recommended as a welcome first step; a sizable portion of this effort is directed toward Africa.
- Emphasis: International support is framed as investment in a global public good — “no one is safe until everyone is safe.”
Building resilience for the future
- Long-term objective: Scale up local manufacturing capacity and strengthen regional supply chains so resilience does not depend on repeated generosity.
- Challenges of relying on imports/donations:
- Health authorities often must accept doses at short notice, often with limited shelf lives, complicating delivery logistics for already-stretched health systems.
- Vaccine manufacturing requirements:
- Specialized equipment, inputs, storage facilities, and skilled labor.
African capacity and initiatives
- Institut Pasteur, Dakar:
- Recognized as a world-class leader in infectious disease response and training.
- With financial assistance from the United States, European Union, and international foundations — and use of some of Senegal’s recent SDR allocation — construction of a new manufacturing facility is underway.
- When complete, it will be one of the first start-to-finish factories on the continent.
- Regional scientific contributions:
- Africa discovered and sequenced the Omicron variant.
- There are 12 production facilities, either in operation or in the pipeline, across six African countries — Algeria, Egypt, Morocco, Rwanda, Senegal, and South Africa — expected to produce a wide range of COVID‑19 vaccines.
Policy recommendations and international actions urged
- Step up cross-border collaboration in science.
- Incentivize technological transfers to diversify the production of vaccines and other life-saving medical tools.
- Provide predictable financing and delivery mechanisms (e.g., support for COVAX and AVAT).
- Close the $23 billion ACT Accelerator financing gap to support Africa-targeted efforts.
- Support “last mile” delivery capacity in countries to complement vaccine supply.
Key statements and quotations
- “Africa vaccinating Africa is necessary—and it is achievable.”
- “To be clear, this international support is not charity. This is a global public good!”
- Louis Pasteur quotation cited: “Science knows no country, because knowledge belongs to humanity, and is the torch which will illuminate the world.”
Source: IMF blog post “Support for Africa’s Vaccine Production is Good for the World” by Kristalina Georgieva, January 12, 2022.